ATE476416T1 - Additionssalze von hemmern des angiotensin konvertierenden enzyms mit no abgebenden säuren, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen - Google Patents

Additionssalze von hemmern des angiotensin konvertierenden enzyms mit no abgebenden säuren, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen

Info

Publication number
ATE476416T1
ATE476416T1 AT08290885T AT08290885T ATE476416T1 AT E476416 T1 ATE476416 T1 AT E476416T1 AT 08290885 T AT08290885 T AT 08290885T AT 08290885 T AT08290885 T AT 08290885T AT E476416 T1 ATE476416 T1 AT E476416T1
Authority
AT
Austria
Prior art keywords
leving
acids
production
pharmaceutical compositions
addition salts
Prior art date
Application number
AT08290885T
Other languages
English (en)
Inventor
Nanteuil Guillaume De
Bernard Portevin
Philippe Gloanec
Jean-Gilles Parmentier
Alain Benoist
Tony Verbeuren
Alain Rupin
Christine Courchay
Serge Simonet
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE476416T1 publication Critical patent/ATE476416T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT08290885T 2007-09-21 2008-09-19 Additionssalze von hemmern des angiotensin konvertierenden enzyms mit no abgebenden säuren, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen ATE476416T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE476416T1 true ATE476416T1 (de) 2010-08-15

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08290885T ATE476416T1 (de) 2007-09-21 2008-09-19 Additionssalze von hemmern des angiotensin konvertierenden enzyms mit no abgebenden säuren, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen

Country Status (43)

Country Link
US (1) US7981920B2 (de)
EP (2) EP2039682B1 (de)
JP (1) JP4903187B2 (de)
KR (1) KR101070056B1 (de)
CN (1) CN101391973A (de)
AP (1) AP2010005204A0 (de)
AR (1) AR068488A1 (de)
AT (1) ATE476416T1 (de)
AU (1) AU2008217013B8 (de)
BR (1) BRPI0804073A2 (de)
CA (1) CA2639700C (de)
CL (1) CL2008002725A1 (de)
CR (1) CR11320A (de)
CY (1) CY1110782T1 (de)
DE (1) DE602008002027D1 (de)
DK (1) DK2039682T3 (de)
EA (1) EA015092B1 (de)
EC (1) ECSP10010040A (de)
ES (1) ES2349493T3 (de)
FR (1) FR2921365B1 (de)
GE (1) GEP20125479B (de)
HN (1) HN2010000533A (de)
HR (1) HRP20100545T1 (de)
JO (1) JO2664B1 (de)
MA (1) MA30320B1 (de)
MX (1) MX2008011954A (de)
MY (1) MY144927A (de)
NI (1) NI201000038A (de)
NZ (1) NZ572988A (de)
PA (1) PA8796701A1 (de)
PE (1) PE20091190A1 (de)
PL (1) PL2039682T3 (de)
PT (1) PT2039682E (de)
RS (1) RS51433B (de)
SA (1) SA08290599B1 (de)
SG (1) SG151200A1 (de)
SI (1) SI2039682T1 (de)
SV (1) SV2010003511A (de)
TN (1) TN2010000111A1 (de)
TW (1) TWI370118B (de)
UY (1) UY31339A1 (de)
WO (1) WO2009074733A2 (de)
ZA (1) ZA200808062B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EP1578413A2 (de) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-hemmer mit antioxidativer und no-donor-wirkung
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1846380A4 (de) * 2005-01-21 2010-02-17 Nicox Sa Zusammensetzungen enthaltend herzkreislaufaktive verbindungen umfassend heterocyclische stickoxyddonorgruppen, und anwendungsverfahren
WO2006102071A1 (en) * 2005-03-18 2006-09-28 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
ATE485261T1 (de) * 2005-11-23 2010-11-15 Nicox Sa Salicylsäurederivate

Also Published As

Publication number Publication date
CA2639700C (fr) 2012-08-28
AP2010005204A0 (en) 2010-04-30
AU2008217013A1 (en) 2009-04-09
SG151200A1 (en) 2009-04-30
JO2664B1 (en) 2012-06-17
BRPI0804073A2 (pt) 2009-06-16
GEP20125479B (en) 2012-04-25
EA200801863A1 (ru) 2009-04-28
FR2921365A1 (fr) 2009-03-27
RS51433B (en) 2011-04-30
MY144927A (en) 2011-11-30
CY1110782T1 (el) 2015-06-10
US7981920B2 (en) 2011-07-19
NZ572988A (en) 2010-07-30
EP2039682B1 (de) 2010-08-04
CN101391973A (zh) 2009-03-25
AU2008217013B2 (en) 2012-08-16
EP2236495A1 (de) 2010-10-06
ECSP10010040A (es) 2010-04-30
DE602008002027D1 (de) 2010-09-16
ES2349493T3 (es) 2011-01-04
CA2639700A1 (fr) 2009-03-21
TWI370118B (en) 2012-08-11
WO2009074733A3 (fr) 2009-08-20
ZA200808062B (en) 2009-11-25
PL2039682T3 (pl) 2010-10-29
KR101070056B1 (ko) 2011-10-04
CR11320A (es) 2010-06-29
AU2008217013A8 (en) 2012-10-04
AU2008217013B8 (en) 2012-10-04
JP4903187B2 (ja) 2012-03-28
CL2008002725A1 (es) 2009-06-12
TW200920352A (en) 2009-05-16
US20090082393A1 (en) 2009-03-26
UY31339A1 (es) 2008-10-31
HN2010000533A (es) 2013-07-08
WO2009074733A2 (fr) 2009-06-18
SA08290599B1 (ar) 2011-05-04
EA015092B1 (ru) 2011-06-30
EP2039682A1 (de) 2009-03-25
DK2039682T3 (da) 2010-11-08
PE20091190A1 (es) 2009-08-09
AR068488A1 (es) 2009-11-18
PA8796701A1 (es) 2009-09-17
HRP20100545T1 (hr) 2010-11-30
NI201000038A (es) 2010-07-15
SV2010003511A (es) 2010-07-29
TN2010000111A1 (fr) 2011-09-26
MX2008011954A (es) 2009-03-20
JP2009137935A (ja) 2009-06-25
FR2921365B1 (fr) 2012-10-12
PT2039682E (pt) 2010-09-27
SI2039682T1 (sl) 2010-10-29
KR20090031298A (ko) 2009-03-25
MA30320B1 (fr) 2009-04-01

Similar Documents

Publication Publication Date Title
ATE441638T1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HK1170224A1 (zh) 有效作為黃嘌呤氧化酶抑制劑的新化合物、該化合物的製備方法和含有該化合物的藥物組合物
ZA201201791B (en) Method for the preparation of 2,5-furandicarboxylic acid and esters thereof
ZA201201974B (en) Method for the preparation of 2,5-furandicarboxylic acid and for the prepartion of the dialkyl ester of 2,5-furandicarboxylic acid
WO2009149956A3 (en) Fusion protein and use thereof
ZA200809002B (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP1996213A4 (de) Verfahren und zusammensetzungen zur portenzierung von pharmazeutika mit amino-säurebasierten medizinischen nahrungsmitteln
BRPI0816640A2 (pt) "método para produzir produtos de proteína estável ácida e produtos assim produzidos"
ATE438645T1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SI2024347T1 (sl) Fenilamino benzoksazolno substituirane karboksilne kisline postopek za njihovo pripravo in njihovauporaba kot zdravila
AP2008004671A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
SMP201000003B (it) Composizione, metodo e preparazione di acidi biliari sintetici.
EP2178891B8 (de) Phosphonigsäuren, -salze und -ester, verfahren zu deren herstellung und ihre verwendung
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
IL193481A0 (en) 4-phenyl-thiazole-5-carboxylic acids and 4 - phenyl - thiazole - 5 - carboxylic acid amides as plk1 inhibitors
ATE537817T1 (de) Nanoteilchen-träger zur verabreichung von arzneimitteln und verfahren zu ihrer herstellung
IL195473A (en) Diphosphate Acetic Acid Derivatives as Glycine Transporter Inhibitors-1, Method for Preparing, Using Pharmaceutical Preparations
EP2212325A4 (de) 2-arylmethylazetidincarbapenem-3-carbonsäureesterderivat oder dessen salz, verfahren zur herstellung davon und dieses enthaltende pharmazeutische zusammensetzung
DE602004014805D1 (de) Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
EP2270145A4 (de) Neues an hyaluronsäure bindendes protein und verfahren zur messung von hyaluronsäure damit
DE602007011817D1 (de) Fermentierte produkte mit ballaststoffen und verfahren zu ihrer herstellung
ATE476416T1 (de) Additionssalze von hemmern des angiotensin konvertierenden enzyms mit no abgebenden säuren, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
HK1209022A1 (en) Amino acid derivatives used as pharmaceutical substances

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2039682

Country of ref document: EP